Rigel Pharmaceuticals Inc
F:RI2A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Rigel Pharmaceuticals Inc
F:RI2A
|
US |
|
Microvast Holdings Inc
NASDAQ:MVST
|
US |
|
R
|
Randstad NV
SWB:RSH
|
NL |
|
C
|
Cintas Corp
LSE:0HYJ
|
US |
|
L
|
Leggett & Platt Inc
LSE:0JTT
|
US |
|
S
|
Seagate Technology Holdings PLC
XBER:847
|
SG |
|
ZTO Express (Cayman) Inc
OTC:ZTOEF
|
CN |
|
L
|
LKQ Corp
SWB:LKQ1
|
US |
|
S
|
Saipem SpA
LSE:0RPI
|
IT |
|
Adient PLC
NYSE:ADNT
|
IE |
|
B
|
Bank of Nova Scotia
NYSE:BNS
|
CA |
|
Third Coast Bancshares Inc
NYSE:TCBX
|
US |
|
H
|
Home Depot Inc
DUS:HDI
|
US |
|
Levi Strauss & Co
NYSE:LEVI
|
US |
|
B
|
Bidvest Group Ltd
JSE:BVT
|
ZA |
|
S
|
Super Group Ltd
JSE:SPG
|
ZA |
|
B
|
Birkenstock Holding PLC
XBER:7PV
|
UK |
|
O
|
Owens Corning
XETRA:O5Q
|
US |
|
M
|
Mitsubishi Estate Co Ltd
XBER:MES
|
JP |
Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals is a specialty drug company that develops and sells medicines made to treat serious blood, cancer, and immune-related diseases. Its main products are prescription drugs used by doctors and hospitals, with a focus on conditions where patients often need long-term treatment and few good options exist. The company’s work starts in the lab, but it also includes getting medicines approved and bringing them to market. Rigel makes money mainly from selling its own drugs, and it can also earn licensing income, milestone payments, and royalties when it partners with other pharmaceutical companies. That means some of its revenue comes directly from patients and healthcare providers through commercial drug sales, while some comes from deals tied to its drug candidates and intellectual property. What makes Rigel’s business model different is that it is a small biotech with both development and commercialization skills. It can create a drug, take it through approval, and either sell it itself in specialized markets or share it with partners to reach more customers. That gives the company more than one way to turn a medicine into revenue, which is common for smaller drugmakers but less so for larger pharmaceutical companies that rely mostly on broad product portfolios.
Rigel Pharmaceuticals is a specialty drug company that develops and sells medicines made to treat serious blood, cancer, and immune-related diseases. Its main products are prescription drugs used by doctors and hospitals, with a focus on conditions where patients often need long-term treatment and few good options exist. The company’s work starts in the lab, but it also includes getting medicines approved and bringing them to market.
Rigel makes money mainly from selling its own drugs, and it can also earn licensing income, milestone payments, and royalties when it partners with other pharmaceutical companies. That means some of its revenue comes directly from patients and healthcare providers through commercial drug sales, while some comes from deals tied to its drug candidates and intellectual property.
What makes Rigel’s business model different is that it is a small biotech with both development and commercialization skills. It can create a drug, take it through approval, and either sell it itself in specialized markets or share it with partners to reach more customers. That gives the company more than one way to turn a medicine into revenue, which is common for smaller drugmakers but less so for larger pharmaceutical companies that rely mostly on broad product portfolios.
Revenue: Rigel reported first-quarter net product sales of $54.9 million, up 26% year over year, and total revenue of $58.8 million.
Outlook: Management kept 2026 guidance unchanged at $275 million to $290 million in total revenue and said it still expects positive net income for the full year.
Seasonality: The quarter was pressured by typical first-quarter reimbursement and access issues, but demand improved in March and the company expects sequential growth to resume in Q2.
R289: The Phase Ib R289 study in lower-risk MDS continues to progress, with dose expansion enrolling and top-line dose-expansion data expected by the end of 2026.
Capital moves: Rigel terminated its Lilly RIPK1 collaboration, expects to regain rights, and also replaced its term loan with a $40 million revolving credit facility.
Portfolio growth: Management said it remains focused on commercial execution, late-stage business development, and expanding the pipeline to support launches between 2026 and 2028.
